RIGL MEXC RealStocks
Own real RIGL shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-17 13:35:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rigel Pharmaceuticals Inc. (New) (RIGL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $43.72, with a market capitalization of $837.18M and a P/E ratio of 2.68. Over the past 52 weeks, its price has ranged from $24.95 to $52.61. This page covers its latest market performance, valuation, price trends and company information.
$837.18M | |
$44.95 | |
$45.64 | |
$43.40 | |
$44.46 | |
105.43K | |
252.28K | |
2.68 | |
$52.61 | |
$24.95 | |
-- | |
-- |
Rigel Pharmaceuticals Inc. (New) (RIGL) is trading at $45.00 in pre-market trading as of 2026-11-17 00:31:00, up 1.21% ($0.54) from the previous close of $44.46
Pre-market trading shows how investors are pricing RIGL before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Rigel Pharmaceuticals Inc. (New) (RIGL) moved from $39.65 to $43.72, representing a gain of 10.25% ($4.07).
The stock traded between $37.60 and $46.21 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 297.94 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 67.9%
RIGL is currently trading at $43.72, placing it 67.9% of the way from its 52-week low of $24.95 to its 52-week high of $52.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 174 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rigel Pharmaceuticals Inc. (New) (RIGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RIGL, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RIGL shares and USD.
RIGL Shares to USD
1.00 RIGL shares = 43.716 USD
Calculations are estimates based on the latest available price and are for reference only.